The Immune Response to Study IR103 in Drug-Naive HIV Patients

The Immune Response has initiated a new arm of a Phase I/II clinical trial investigating IR103, the company's newest product candidate for the treatment of HIV.

This new arm will enroll HIV patients who have not yet begun highly active antiretroviral therapy (HAART) and who will receive IR103, Remune, or saline over 28 weeks. The new drug-naive arm will enroll at two sites in the UK and one site in Canada.

The study, originated in 2004, has already enrolled 45 HIV patients receiving HAART at the three sites in Canada and the UK.